Pfizer and BioNTech to Co-develop Potential COVID-19 Vaccine
BioNTech SE - American Depositary Shares (BNTX)
Company Research
Source: GlobeNewswire
Companies will jointly develop BioNTech’s mRNA-based vaccine candidate BNT162 to prevent COVID-19 infection Collaboration aims to accelerate global development of BNT162, leveraging expertise and resources of both companies Builds on 2018 agreement to jointly develop an mRNA-based influenza vaccine NEW YORK and MAINZ, Germany, March 17, 2020 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech) today announced that the companies have agreed to a letter of intent regarding the co-development and distribution (excluding China) of a potential mRNA-based coronavirus vaccine aimed at preventing COVID-19 infection. The companies have executed a Material Transfer and Collaboration Agreement to enable the parties to immediately start working together. The collaboration aims to accelerate development of BioNTech’s potential first-in-class COVID-19 mRNA vaccine program, BNT162, which is expected to enter clinical testing by the end of April 20
Show less
Read more
Impact Snapshot
Event Time:
BNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTX alerts
High impacting BioNTech SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BNTX
News
- BioNTech SE (NASDAQ: BNTX) is now covered by analysts at Berenberg Bank. They set a "buy" rating and a $130.00 price target on the stock.MarketBeat
- BioNTech SE (NASDAQ: BNTX) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating. They now have a $125.00 price target on the stock, up previously from $110.00.MarketBeat
- BioNTech SE (NASDAQ: BNTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $150.00 price target on the stock.MarketBeat
- BioNTech SE (NASDAQ: BNTX) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $171.00 price target on the stock.MarketBeat
- BioNTech to Acquire Biotheus to Boost Oncology StrategyGlobeNewswire
BNTX
Earnings
- 11/4/24 - Beat
BNTX
Sec Filings
- 11/15/24 - Form 144
- 11/14/24 - Form 6-K
- 11/13/24 - Form 6-K
- BNTX's page on the SEC website